viewMeiraGTx Holdings PLC

MeiraGTx surges on collaboration with J&J unit on retinal diseases

The arrangement calls for cooperation in clinical development and preclinical programs

A human eye
Last June, eye-focused MeiraGTx raised $75 million in its IPO

MeiraGTx Holdings PLC (NASDAQ:MGTX) rallied Thursday after announcing that it will team up with a Johnson & Johnson (NYSE:JNJ) unit to develop and commercialize gene therapies for the treatment of inherited retinal diseases.

Under the deal, the gene therapy company said it will collaborate with Janssen Pharmaceuticals Inc in the clinical development of product candidates for achromatopsia caused by mutations in either CNGB3 or CNGA3 and X-linked retinitis pigmentosa (XLRP).

Shares climbed 30% to $12.40 in Nasdaq trading.

READ: Johnson & Johnson third-quarter results beat estimates; raises guidance for 2018

In addition, according to New York-based MeiraGTx, it’s working with Janssen on its pre-clinical programs for inherited retinal diseases (IRDs).

“By combining Janssen’s extensive clinical, regulatory and commercial expertise and global reach with MeiraGTx’s deep experience in gene therapy development and manufacturing, we aim to accelerate the development of our pipeline of potential IRD gene therapies to address the needs of patients globally,” Alexandria Forbes, president and CEO of MeiraGTx, said in a statement.

Last June, the company raised $75 million in its IPO by offering 5 million shares at $15.

Contact Dennis Fitzgerald at [email protected]

Quick facts: MeiraGTx Holdings PLC

Price: 12.32 USD

Market: NASDAQ
Market Cap: $460.3 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Anteris Technologies 'delivering on its goals despite pandemic'

Anteris Technologies Ltd's (ASX:AVR) Wayne Paterson tells Proactive's Andrew Scott the recent name change from Admedus is to reflect the single focus they have on structural heart and leveraging its assets into much more higher-value propositions. Paterson updates on its main trials which are...

3 hours, 39 minutes ago

2 min read